Healthcare / Medical DevicesTaipei Exchange
$13.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-23.4M · quality 48.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$309M
P/E
N/A
•EV/EBITDA
43.0x
↑ROE
-2.8%
↓Gross Margin
17.4%
↓Debt/Equity
0.50
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.5%
FCF CAGR
—
FCF margin
-4.7%
FCF / Net income
2.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $499.7M · net income $-7.9M · FCF $-23.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $499.7M | $499.7M | $451.1M | $470.2M | $463.5M |
| Net Income | $-7.9M | $-7.9M | $17.3M | $21.0M | $25.4M |
| EBITDA | $7.6M | $7.6M | $34.5M | $44.1M | $46.9M |
| EPS | — | — | 0.73 | 0.88 | 1.06 |
| Gross Margin | 17.4% | 17.4% | 21.3% | 24.6% | 23.2% |
| Operating Margin | -1.3% | -1.3% | 0.8% | 5.3% | 4.0% |
| Net Margin | -1.6% | -1.6% | 3.8% | 4.5% | 5.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.50 | 0.50 | 0.36 | 0.38 | 0.39 |
| Current Ratio | 2.43 | 2.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-23.4M | $-23.4M | $-46.7M | $45.7M | $-10.0M |
| Returns | |||||
| ROE | -2.8% | -2.8% | 5.7% | 6.9% | 8.2% |
| Valuation | |||||
| P/E | — | — | 31.58 | 29.66 | 17.64 |
| EV/EBITDA | 42.98 | 42.98 | 15.41 | 12.33 | 8.30 |
| P/B | 1.10 | 1.10 | 1.81 | 2.04 | 1.45 |
| Growth & Yield | |||||
| Revenue Growth | 10.8% | 10.8% | -4.1% | 1.4% | — |
| EPS Growth | — | — | -17.0% | -17.0% | — |
| Dividend Yield | 5.1% | 5.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.73 → n/d
Residual
-35.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.